COMPUMED ANNOUNCES KODAK CHINA INSTALLS FIRST OSTEOGRAMŽ-ENHANCED DIGITAL X-RAY PLATFORM FULLY INTEGRATED OSTEOGRAM FUNCTIONS SEAMLESSLY TO PROVIDE COST-EFFECTIVE OSTEOPOROSIS TESTING

LOS ANGELES, Nov 27, 2006 -- CompuMed, Inc. (CMPD.OB) -- a medical informatics company leading the development of advanced imaging technology for cost-effective analysis and monitoring - announced today that the first OsteoGram-enhanced KODAK DIRECTVIEW DR 3000 platform has been installed in Wuxi, China.

CompuMed's OsteoGram is a software-based system for the screening, diagnosing and monitoring of osteoporosis. The OsteoGram provides an accurate, low-cost alternative to DXA bone mineral density (BMD) testing. Earlier this year, CompuMed announced a licensing agreement that enables Kodak Electronic Products Shanghai Co., LTD (KEPS) to enhance its market-leading digital radiography (DR) and computed radiography (CR) systems with CompuMed's proprietary OsteoGram software. KEPS is a wholly owned subsidiary of the Eastman Kodak Company (NYSE: EK).

"We are pleased to complete the project to integrate our OsteoGram software with Kodak's DR 3000 platform," said CompuMed CEO Jerry McLaughlin. "Now we can begin marketing the first-of-its-kind integrated system to penetrate the world's largest osteoporosis market."

According to China's 2000 national census, approximately 100 million of its citizens suffer from various stages of osteoporosis, making China the nation with the world's highest number of osteoporosis patients. The annual medical cost to treat those affected by the disease is estimated to be about 15 billion Yuan ($84 billion US), a figure that does not take into account the significant strain osteoporosis incurs on China's national healthcare program.

CompuMed is planning to leverage its expertise in computer-aided diagnostics to provide solutions and services that improve healthcare provider workflow and patient care, while reducing costs. The OsteoGram's benefits in terms of cost and efficiency facilitate wider osteoporosis screening and treatment for at-risk patients. It is far less costly and cumbersome to use than conventional BMD testing systems, which require dedicated and expensive equipment, computers, office space and staff.

CompuMed's OsteoGram is a software-based system for screening, diagnosing and monitoring osteoporosis. It provides an accurate, low-cost alternative to DXA bone mineral density (BMD) screening, and can be utilized in conjunction with rapidly proliferating digital (i.e., filmless) x-ray equipment, as well as existing film-based machines. CompuMed is planning to leverage its expertise in computer aided diagnosis represented by the OsteoGram to provide solutions and services designed to improve the workflow of healthcare providers, improve patient's care and reduce costs. The OsteoGram's vast benefits in terms of cost and efficiency facilitate wider osteoporosis screening and treatment of at-risk patients. It is far less costly and cumbersome to use than conventional BMD testing systems, which require dedicated and expensive equipment, computers, office space and staff.

About CompuMed

Founded in 1973, CompuMed, Inc. (CMPD.OB) is leading the development of advanced imaging and medical informatics to provide cost effective analysis and monitoring solutions. The Company focuses on cardiovascular and musculoskeletal diseases and other diseases associated with aging populations. The Company has unique expertise in telemonitoring, imaging and analysis, which it is deploying to provide solutions and services designed to improve the workflow of healthcare providers, improve patient's care and reduce costs. The company's core products are the OsteoGram and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The CardioGram has the additional capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning CompuMed's plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission. All such forward-looking statements are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

CONTACT: Susan Tellem - Tellem Worldwide, +1 (310) 479-6111 x.15, stellem@tellem.com